Our new unit at St George's Hospital is open for business

January 2004

8th January 2004Our new unit at St George's Hospital is open for businessThe opening of our second unit makes Richmond Pharmacology the largest phase I CRO in the UK. Our total capacity across the two sites has increased to 90 beds.The new unit is located in the Knightsbridge Wing of St George’s Hospital, Tooting, London. Situated within refurbished, access-controlled facilities and run by the same dedicated and highly trained team of over 80 staff already working at our Atkinson Morley’s Hospital Unit.We have made a further significant investment in our state of the art equipment with networked 12 lead Marquette ECGs at every bed.St George’s Healthcare Trust is one of the largest and busiest National Health Service Trusts in the country. As well as providing general and acute services, the hospital offers a range of specialist, teaching and research facilities with links to the services of St Georges Hospital Medical School.St George’s Hospital Medical School. The even closer proximity to the Medical School provides further opportunities for joint academic research, specialist studies or patient trials.Richmond Pharmacology’s new unit is one of the only commercial Phase I CROs with facilities located within the same site as both the Teaching Hospital and Medical School.To request a brochure on our new facilities or to arrange a site visit please contact Claire Tucker today.

Latest news

Upcoming Event

On Helix, Transforming new medicine discovery

13-14 July 2020
Richmond Pharmacology will be showcasing a presentation on Adaptive Early Phase Clinical Trials as part of the ON HELIX digital event.
View event

COVID-19 – External Monitoring Guidelines

July 1, 2020
Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewing Public Health England guidance.
Read more

First transdermal patch to treat schizophrenia hits market

March 18, 2020
The US Food and Drug Administration (FDA) has officially approved a transdermal patch to treat schizophrenia developed by Hisamitsu Pharmaceutical Co following successful
Read more

Statement: COVID-19

March 23, 2020
Richmond Pharmacology are continuously risk-assessing our activity in relation to the COVID-19 crisis and we are evaluating what activity can continue, what precautions need to be put in place and what needs to be suspended.
Read more